SCHEMBL633813

SCHEMBL633813

O=C(Nc1ccc(OC(F)(F)F)cc1)c1sccc1NCc1ccnc2[nH]ccc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.75
KIT P10721 2/20 0.75
RAF1 P04049 1/20 0.75
LCK P06239 1/20 0.75
RET P07949 1/20 0.75
CYP3A4 P08684 1/20 0.75
MAP3K20 Q9NYL2 1/20 0.75
RIPK3 Q9Y572 1/20 0.75
NTRK1 P04629 2/20 0.44
FLT1 P17948 3/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 1/20 0.42
ABL1 P00519 3/20 0.42
MET P08581 3/20 0.41
BCR P11274 1/20 0.41
TTBK1 Q5TCY1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3395765 0.87 KDR (0.71) KDRKITRAF1LCKRET
Osi-930 SCHEMBL633719 0.86 KDR (1.00) KDRKITRAF1LCKRET
Osi-930 SCHEMBL29352171 0.86 KDR (1.00) KDRKITRAF1LCKRET
SCHEMBL633661 0.85 KDR (0.60) KDRKITRAF1LCKRET
SCHEMBL3362720 0.83 KDR (0.79) KDRKITRAF1LCKRET
SCHEMBL3359832 0.83 KDR (0.79) KDRKITRAF1LCKRET
SCHEMBL3361575 0.83 KDR (0.81) KDRKITRAF1LCKRET
SCHEMBL20805543 0.83 KDR (0.78) KDRKITRAF1LCKRET
SCHEMBL3364485 0.83 KDR (0.81) KDRKITRAF1LCKRET
SCHEMBL3359202 0.82 KDR (0.77) KDRKITRAF1LCKRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP claimed
JP-4685755-B2 2011-05-18 JP claimed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO claimed
CN-100471841-C (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2009-03-25 CN claimed
EP-1590328-A4 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2007-09-19 EP claimed
CN-1723200-A (2-carboxamido) (3-amino) thiophene compounds OSI PHARM INC (US) 2006-01-18 CN claimed
EP-1590328-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI Pharmaceuticals, Inc. (US) 2005-11-02 EP claimed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US claimed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US claimed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO claimed
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP disclosed
EP-1590328-B1 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARM INC (US) 2012-02-22 EP disclosed
WO-2010088000-A2 ANTIFIBROTIC COMPOUNDS AND USES THEREOF ANGION BIOMEDICA CORP. (US) 2010-08-05 WO disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-7696225-B2 (2-carboxamido)(3-Amino) thiophene compounds OSI PHARMACEUTICALS, INC. (US) 2010-04-13 US disclosed
US-6949563-B2 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2005-09-27 US disclosed
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds CREW ANDREW P (US) 2005-09-01 US disclosed
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds OSI PHARMACEUTICALS, INC. 2005-07-14 US disclosed
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds OSI PHARMACEUTICALS, INC. 2004-09-23 US disclosed
WO-2004063330-A2 (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS OSI PHARMACEUTICALS, INC. (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186124-A1 (2-carboxamido)(3-amino)thiophene compounds ABL1, NAT1, KRAS KDR 869/4885KIT 1833/4885RAF1 649/4885
US-20050154014-A1 (2-carboxamido)(3-amino) thiophene compounds AADAC, PAM, TPMT KDR 2418/4885KIT 4457/4885RAF1 3013/4885
US-20050192320-A1 (2-Carboxamido)(3-amino)thiophene compounds PCNA, MKI67, TPMT KDR 1769/4885KIT 289/4885RAF1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.